xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

431

Orlandi et al.

1. MH saline spray in 1 nostril 2. placebo in the other symptom scores, endoscopy grades or culture results on bothsides Wong 1228 2011 4 Case reports 2 patients after failing SNOT 22; subjective symptoms; Duration 12 weeks

discomfort and pain on the removal of the packings between groups; trend toward less pain for

the MH-soaked Merocel MMS

No statistically significant difference between the 2

groups but trend toward reduced mucosal

inflammation in the MH group Duration 30 days

Patients 1 and 2: symptoms and endoscopic examination improved

drastically; side effects:

patient 1 had irritation

symptoms and patient 2 hadnone

No significant difference in

Authors Year LOE Type of Study Patient Groups Clinical Endpoint Outcomes Chang 1229 2011 2 Double-blind control trial VAS Pain scale; Duration 7 days

No significant difference in

analysis of mucosal

biopsies to assess for inflammation.

SNOT22;

Endoscopic grading; Sinus cultures

Histopathologic

Endoscopic exam

Thamboo 1227 2011 2 Single-blind RCT 34 patients with surgically recalcitrant AFRS treated withdaily

3 groups: 48 patients (16 each group) after ESS

Budesonide (0.25 mg/mL), MH (50%) or gentamicin (40 mg/mL) soaked Merocel MMS

Nonmedicated Merocel in contralateral side

Biopsies also taken from the middle meati after packing removal and blinded

pathologists rated the level of mucosal inflammation

maximal management of AFRS

MH in sinus rinse bottles 120 mL per side twice a day

TABLE IX-40 (Continued)